Abciximab plus heparin versus bivalirudin : ISAR-REACT-4

Aug 23, 2014

40 likes | 170 Views

Abciximab plus heparin versus bivalirudin : ISAR-REACT-4.

Share Presentation

Embed Code

Link

major bleeding rate waslowerwithbivalirudin
composite death
kastrati nejm
endpoint
adverse events
major bleedingat

razi

Download Presentation

Abciximab plus heparin versus bivalirudin : ISAR-REACT-4

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

Abciximab plus heparin versus bivalirudin: ISAR-REACT-4 Objective: to evaluate the efficacy of abciximab plus heparin versus bivalirudin in patients with non-ST-elevation MI undergoing PCIStudy: multicenterdouble-blindrandomizedcontrolled trialPopulation: patients withnon-ST segment elevation MI undergoing PCI Endpoint: composite death, re-MI, urgent TVR or major bleedingat 30 days
Abciximab plus heparin versus bivalirudin: ISAR-REACT-4
Abciximab plus heparin versus bivalirudin: ISAR-REACT-4
Abciximab plus heparin versus bivalirudin: ISAR-REACT-4 Conclusion abciximab plus heparinwasassociatedwithsimilar major adverse events as bivalirudin. The major bleeding rate waslowerwithbivalirudin. Kastrati NEJM 2011;365:1980-9

Substance-related disorders

Substance-related disorders. Done by : shaker ala’araj abdelhadi melhem mothana bani yaseen. Objectives. Define tolerance , intoxication, substance use disorder ,withdrawal . Know the stimulants , depressants , and their actions .

1.09k views • 72 slides

Heparin-Induced Thrombocytopenia (HIT)

Heparin-Induced Thrombocytopenia (HIT). Treatment with danaparoid (Orgaran  ). Management of HIT – treatment. Stop all heparin (both unfractionated and low-molecular-weight heparin) Initiate alternative non-heparin anticoagulant because of high risk of symptomatic thrombosis

1.18k views • 35 slides

Understanding Heparin-Induced Thrombocytopenia (HIT): Historical and Clinical Perspectives

Understanding Heparin-Induced Thrombocytopenia (HIT): Historical and Clinical Perspectives. Heparin-Induced Thrombocytopenia. Heparin is a widely used anticoagulant drug for the treatment and prevention of thromboembolic disorders

1.02k views • 58 slides

HEPARIN INDUCED THROMBOCYTOPENIA (HIT)

HEPARIN INDUCED THROMBOCYTOPENIA (HIT). HEPARIN-INDUCED THROMBOCYTOPENIA. Causative agents. Unfractionated heparin (UFH) (beef > pork) Continuous iv infusion Cardiopulmonary bypass Low dose sq Heparin flushes Heparin-bonded catheters Low molecular weight heparin

1.7k views • 51 slides

Anticoagulants

Anticoagulants. NURS 1950 Pharmacology I. Objective 1: identify general reasons anticoagulants are given. Objective 2: identify the cells in the body that release heparin Objective 3: describe the actions of heparin. Objective 4: list the appropriate routes to administer heparin.

703 views • 34 slides

Randomized Comparison UpstrEam Standard Dose Tirofiban Versus DownstrEam High-doSe Tirofiban or Abciximab in High-risk A

Patients treated with upstream tirofiban regimen would have a better tissue-level perfusion and reduced Troponin I release after interventions compared with patients who were treated with downstream HBD tirofiban and abciximab regimenNo significant difference would have found between downstream HB

400 views • 10 slides

Is Bivalirudin Monotherapy Sufficient for Diabetic Patients with Acute Coronary Syndrome Undergoing PCI?

Is Bivalirudin Monotherapy Sufficient for Diabetic Patients with Acute Coronary Syndrome Undergoing PCI?. Frederick Feit, Steven Manoukian, Ramin Ebrahimi, Charles Pollack, Magnus Ohman, Michael Attubato and Gregg Stone. Is Bivalirudin Monotherapy Sufficient for Diabetic Patients

362 views • 22 slides

Is Bivalirudin and Femoral Access as Safe as Radial Access?

Is Bivalirudin and Femoral Access as Safe as Radial Access?. Philippe Genereux, MD, Columbia University Medical Center New York Presbyterian Hospital New York, NY ACC 2011, New Orleans . Disclosure. None. 1) Bleeding is frequent. Bivalirudin. Heparin.

494 views • 33 slides

Motivated To Teach The At-Risk: When to react and when not to react

Motivated To Teach The At-Risk: When to react and when not to react. Daily Attitude. Every morning in Africa at sunrise the gazelle wakes up knowing he must run faster than the fastest lion or he will not survive.

222 views • 11 slides

UNCTAD-ISAR Accounting and Financial Reporting Guidelines for SMEs

UNCTAD-ISAR Accounting and Financial Reporting Guidelines for SMEs. The Exchange – World Bank Amman, Jordan 18 June 2013. UNCTAD-ISAR -Accounting by SMEs. Outline: Introduction to UNCTAD-ISAR Background to the work on Accounting by SMEs Main features of the SMEGAs

344 views • 17 slides

HEAT PPCI

HEAT PPCI. H ow E ffective are A ntithrombotic T herapies in PPCI. Heparin versus Bivalirudin in PPCI. Dr Adeel Shahzad Dr Rod Stables (PI) Liverpool Heart and Chest Hospital Liverpool, UK. Background. Anti-thrombotic therapy in PPCI

1.14k views • 79 slides

Heparin-induced thrombocytopenia (HIT)

PCI Vascular devices VTE prophylaxis Postop anticoag. Where Do We Use Heparin?. Heparin-induced thrombocytopenia (HIT). The Overuse of Heparin.

241 views • 1 slides

Bivalirudin with Provisional GPIIb/IIIa Inhibition – the Data are Clear!

Bivalirudin with Provisional GPIIb/IIIa Inhibition – the Data are Clear!. Gregg W. Stone MD. Columbia University Medical Center Cardiovascular Research Foundation. Bivalirudin vs. Heparin + GPI (n=18,819) 30d TIMI major or minor bleeding by treatment and study . p < 0.0001. p < 0.0001.

362 views • 22 slides

React

React. React. A library for creating user interfaces. React. Renders your UI and responds to events. React. Plays nicely with your stack. Build components , not templates. Separation of concerns:. Reduce coupling , increase cohesion. Coupling is:.

764 views • 31 slides

B avarian R eperfusion A lternati V es E valuation Kastrati et al AHA 2003

B avarian R eperfusion A lternati V es E valuation Kastrati et al AHA 2003. Aim - To compare pre-treatment with reteplase and abciximab with abciximab alone on clinical outcome after PCI for STEMI Methods 253 patients randomized < 12hrs symptoms

242 views • 16 slides

ISAR-REACT 3

ClinicalTrials.gov Identifier NCT00262054. Bivalirudin Versus Unfractionated Heparin in Biomarker Negative Patients With Stable and Unstable Angina Undergoing PCI. ISAR-REACT 3.

400 views • 12 slides

ACUITY: Death, MI, revascularization for ischemia, or major bleeding by 30 days

15. 11.8. 11.7. 10.1. 10. 5. 0. ACUITY: Death, MI, revascularization for ischemia, or major bleeding by 30 days. %. Heparin + GPI IIb/IIIa. Bivalirudin + GPI IIb/IIIa. Bivalirudin alone. p = 0.015 for superiority of bivalrudin alone vs. hep+GPI

190 views • 6 slides

Hyperanalytic Wavelet Packets

Hyperanalytic Wavelet Packets. Ioana Firoiu, Dorina Isar , Jean-Marc Boucher, Alexandru Isar. WISP 2009, Budapest, Hungary. Introduction. Wavelet techniques based on the Discrete Wavelet Transform (DWT) Advantages Sparsity of coefficients Disadvantages

357 views • 18 slides

EPIC: Balloon Angioplasty

Placebo + heparin (ACT  300 sec) (n=696). Abciximab 0.25mg/kg bolus + heparin (ACT  300 sec) (n=395). Abciximab 0.25mg/kg bolus / 10 µg/kg infusion + heparin (ACT  300 sec) (n=708). EPIC: Balloon Angioplasty. Primary Endpoint: Death, MI, UTVR at 30 days. 4.5%  ( P <0.004).

214 views • 2 slides

Understanding Heparin-Induced Thrombocytopenia (HIT): Historical and Clinical Perspectives

1.09k views • 58 slides

More Related